P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium

L. Silverman, A. Verma, R. Odchimar-Reissig, A. LeBlane, V. Najfeld, J. Gabrilove, L. Isola, I. Espinoza-Delgado, J. Zwiebel

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)S135-S136
JournalLeukemia Research
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - May 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this